File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes

TitleDistinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes
Authors
Issue Date2012
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58 How to Cite?
AbstractAims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P < 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P < 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic β-cell autoimmunity. Copyright © 2012 by The Endocrine Society.
Persistent Identifierhttp://hdl.handle.net/10722/163504
ISSN
2014 Impact Factor: 6.209
2014 SCImago Journal Rankings: 2.625
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXiao, Yen_US
dc.contributor.authorXu, Aen_US
dc.contributor.authorLaw, LSCen_US
dc.contributor.authorChen, Cen_US
dc.contributor.authorLi, Hen_US
dc.contributor.authorLi, Xen_US
dc.contributor.authorYang, Len_US
dc.contributor.authorLiu, Sen_US
dc.contributor.authorZhou, Zen_US
dc.contributor.authorLam, KSLen_US
dc.date.accessioned2012-09-05T05:32:39Z-
dc.date.available2012-09-05T05:32:39Z-
dc.date.issued2012en_US
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58en_US
dc.identifier.issn0021-972Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/163504-
dc.description.abstractAims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P < 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P < 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic β-cell autoimmunity. Copyright © 2012 by The Endocrine Society.en_US
dc.languageengen_US
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_US
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAutoimmunity - Physiologyen_US
dc.subject.meshBlood Glucose - Analysisen_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshChilden_US
dc.subject.meshDiabetes Mellitus - Blood - Classificationen_US
dc.subject.meshDiabetes Mellitus, Type 1 - Blooden_US
dc.subject.meshDiabetes Mellitus, Type 2 - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshFibroblast Growth Factors - Analysis - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshInsulin-Secreting Cells - Immunologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.titleDistinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetesen_US
dc.typeArticleen_US
dc.identifier.emailLam, KSL:ksllam@hku.hken_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1210/jc.2011-1930en_US
dc.identifier.pmid22013098-
dc.identifier.scopuseid_2-s2.0-84862928486en_US
dc.identifier.hkuros204675-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84862928486&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume97en_US
dc.identifier.issue1en_US
dc.identifier.spageE54en_US
dc.identifier.epageE58en_US
dc.identifier.isiWOS:000300393800008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridXiao, Y=36464707600en_US
dc.identifier.scopusauthoridXu, A=55212499600en_US
dc.identifier.scopusauthoridLaw, LSC=55212861700en_US
dc.identifier.scopusauthoridChen, C=37025734000en_US
dc.identifier.scopusauthoridLi, H=54786669500en_US
dc.identifier.scopusauthoridLi, X=54988955800en_US
dc.identifier.scopusauthoridYang, L=9747287700en_US
dc.identifier.scopusauthoridLiu, S=50361659300en_US
dc.identifier.scopusauthoridZhou, Z=8417885800en_US
dc.identifier.scopusauthoridLam, KSL=8082870600en_US
dc.customcontrol.immutablejt 130419-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats